• Among various types of surface epithelial ovarian carcinoma, clear cell adenocarcinoma often has a particularly poor prognosis even when diagnosed in stage I. It is resistant to existing anticancer drugs and appears to have different biological properties to other histological types of ovarian cancer. (elsevierpure.com)
  • Here, we report an unusual combination of bilateral ovarian SMBT and clear cell carcinoma associated with polypoid endometriosis of the colon, in a 62-year-old woman. (hindawi.com)
  • To the best of our knowledge, this is the first case of this unusual combination of ovarian seromucinous tumor and clear cell carcinoma to be reported in the English literature. (hindawi.com)
  • A few studies have reported tumors coexisting with SMBTs, such as endometrioid adenocarcinoma [ 4 ] and squamous cell carcinoma [ 5 ]. (hindawi.com)
  • Here, we describe the first case, to our knowledge, of an unusual combination of ovarian SMBT and clear cell carcinoma. (hindawi.com)
  • Ovarian clear cell carcinoma (CCC)" Encyclopedia , https://encyclopedia.pub/entry/10310 (accessed November 28, 2023). (encyclopedia.pub)
  • Ovarian clear cell carcinoma (CCC) exhibits unique characteristics, including slow growth, glycogen accumulation in the cytoplasm, and poor prognosis for stress resistance. (encyclopedia.pub)
  • The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. (biomedcentral.com)
  • However, as explained below, recent morphologic findings and molecular analyses have demonstrated that each morphologic subtype of ovarian carcinoma might be derived from a Müllerian-type epithelium. (biomedcentral.com)
  • Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? (nih.gov)
  • Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. (nih.gov)
  • Benign, of low malignant potential, and associated with invasive clear cell carcinoma. (nih.gov)
  • Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary. (nih.gov)
  • To define molecular and biochemical profiles associated with the duration of progression-free survival in platinum-sensitive recurrent ovarian, peritoneal primary or fallopian tube carcinoma treated with combination chemotherapy with or without bevacizumab followed with or without maintenance bevacizumab therapy in the presence or absence of secondary surgical cytoreduction. (ucsf.edu)
  • The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common. (bvsalud.org)
  • Case Presentation: In our hospital, we recently summarized two patients with ovarian clear cell carcinoma with similar characteristics. (bvsalud.org)
  • Unfortunately, the cyst recurred after surgery, and the histological diagnosis was clear cell carcinoma. (bvsalud.org)
  • Se diferencian 3 tipos de cáncer de ovario en función del tejido celular en el que se origina el cáncer: carcinoma epitelial, tumores de células germinales y tumores del estroma. (espacio-seram.com)
  • Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. (espacio-seram.com)
  • The exact cause is not fully understood, but it appears that hormones play an important role in genesis of the ovarian carcinoma. (cancertame.com)
  • Studies have shown that the risk of ovarian carcinoma is reduced to 50 per cent during pregnancy due to hormonal factors. (cancertame.com)
  • The use of contraceptive pills also lowers the risk of ovarian carcinoma because it creates a hormonal balance in the body that is similar to the pregnancy. (cancertame.com)
  • Studies have revealed that the nulliparous women are more likely to develop the ovarian carcinoma. (cancertame.com)
  • Those women, who had suffered from cancer of the breast, intestine or the rectum, also have a higher risk of the ovarian carcinoma. (cancertame.com)
  • It has been observed that those women, who had a positive family history of the breast or the ovarian cancer, have a higher risk of the ovarian carcinoma. (cancertame.com)
  • About 85 per cent of the ovarian tumours are carcinomas, which include mucinous cystadenocarcinoma, serous cystadenocarcinoma, clear cell cystadenocarcinoma, endometrioid adenocarcinoma and undifferentiated carcinoma. (cancertame.com)
  • The major symptoms of ovarian carcinoma include palpable abdominal mass, ascites and weight loss. (cancertame.com)
  • In stage I of the ovarian carcinoma, the tumour is localised in one or both of the ovaries. (cancertame.com)
  • In stage IV, the ovarian carcinoma metastasises to the liver and extra abdominal organs. (cancertame.com)
  • Recurrent ovarian carcinoma is the one that reappears after an apparent recovery in response to the initial treatment. (cancertame.com)
  • Procedures used in diagnosis and evaluation of the ovarian carcinoma include pelvic examination, X-rays, ultrasound, CT scan, IVP, exploratory laparotomy and biopsy. (cancertame.com)
  • The estimation of CA 125 and CEA is important in the follow-up of ovarian carcinoma patients. (cancertame.com)
  • The raised level of CA 125 indicates presence of the ovarian carcinoma in the body, whereas the raised level of CEA indicates advanced stage of the ovarian carcinoma. (cancertame.com)
  • The germ cell tumours include dysgerminoma, endodermal sinus tumour, embryonal carcinoma, malignant teratoma and choriocarcinoma. (cancertame.com)
  • Human colon colorectal carcinoma cell line from a male organism. (maayanlab.cloud)
  • undifferentiated carcinoma), Recurrent, platinum resistant ovarian cancer (defined as progression within (kaiser.org)
  • To be eligible for enrollment, patients had to have a histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with an epithelial cell type of either high-grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, or mixed epithelial carcinoma. (onclive.com)
  • Materials and Methods ES2 ovarian clear cell carcinoma cells and SKOV3 adenocarcinoma cells were treated with palmitic acid or EPA, followed RepSox (SJN 2511) by flow cytometry and cell counting to measure apoptosis and proliferation, respectively. (biotech-angels.com)
  • Human ovarian cancer cell lines TOV21G (representing clear cell ovarian carcinoma) and TOV112D (representing endometrioid adenocarcinoma) were purchased from American Type Culture Collection (Manassas, VA). The human ovarian epithelial-serous cell line COV504 was purchased from Sigma Aldrich (St. Louis, MO). (biomedcentral.com)
  • 15] revealed that SOD2 is more strongly expressed in ovarian clear cell carcinoma than in other epithelial ovarian cancer subtypes and that SOD2 is a pro-tumorigenic or metastatic factor. (bibf1120.com)
  • Comprehensive Analysis of mC RNA Methylation Regulator Genes in Clear Cell Renal Cell Carcinoma. (cdc.gov)
  • This article focuses on treatment of squamous cell and adenocarcinoma histologies and does not include the management of vaginal dysplasia or vaginal carcinoma in situ. (medscape.com)
  • The relationship between blood pressure and risk of renal cell carcinoma. (who.int)
  • Epidemiology of Renal Cell Carcinoma: 2022 Update. (who.int)
  • Mycotoxin Exposure and Renal Cell Carcinoma Risk: An Association Study in the EPIC European Cohort. (who.int)
  • Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. (who.int)
  • [ 3 , 4 ] The term "pseudomesotheliomatous carcinoma" was first applied by Harwood and colleagues in 1976 to 6 cases of peripheral lung adenocarcinoma that closely mimicked mesothelioma. (medscape.com)
  • The present study was conducted using cell lines derived from ovarian clear cell adenocarcinoma in order to identify genes associated with the acquisition of malignant potential by this type of cancer. (elsevierpure.com)
  • Primers were established using these base sequences and the level of expression in each cancer cell line was determined by real-time PCR. (elsevierpure.com)
  • Finally, EPB41L4A-AS2 inhibited breast cancer cell proliferation, migration and invasion and induced cell apoptosis in vitro. (cancerindex.org)
  • Proteomic grade correlations identified protein kinases having functional impact in vitro in uterine endometrial cancer cells, including MAP3K2, MASTL, and TTK. (nih.gov)
  • It was under development for the treatment of relapsed or refractory multiple myeloma, glioblastoma multiforme, blood cancer, metastatic non-small cell lung cancer and malignant pleural mesothelioma. (pharmaceutical-technology.com)
  • It's pipeline products include Voyager-V1 for solid tumors, MV-NIS for bladder cancer, Voyager-V1 + pembrolizumab for non-small cell lung cancer, head and neck cancer, Voyager-V1 + cemiplimab for multiple cancer indications among others. (pharmaceutical-technology.com)
  • Vyriad conducts investigator sponsored trials targeted against myeloma, endometrial cancer, multiple myeloma, T cell lymphoma medulloblastoma, and others. (pharmaceutical-technology.com)
  • Ovarian cancer is a leading cause of cancer death among women in the United States and it has the highest mortality rate of all gynecologic cancers. (nih.gov)
  • Internationally, there is a five-fold variation in incidence and mortality of ovarian cancer, which suggests a role for environmental factors, including diet. (nih.gov)
  • We evaluated dietary nitrate and nitrite intake and epithelial ovarian cancer in the National Institutes of Health (NIH)-AARP Diet and Health Study, including 151 316 women aged 50-71 years at the time of the baseline questionnaire in 1995-1996. (nih.gov)
  • Through 31 December 2006, 709 incident epithelial ovarian cancer cases with complete dietary information were identified. (nih.gov)
  • Using Cox proportional hazards regression to estimate hazard ratios and 95% confidence intervals (CIs), women in the highest intake quintile of dietary nitrate had a 31% increased risk (95% CI: 1.01-1.68) of epithelial ovarian cancer, compared with those in the lowest intake quintile. (nih.gov)
  • Although there was no association for total dietary nitrite, those in the highest intake category of animal sources of nitrite had a 34% increased risk (95% CI: 1.05-1.69) of ovarian cancer. (nih.gov)
  • There were no clear differences in risk by histologic subtype of ovarian cancer. (nih.gov)
  • Our findings suggest that a role of dietary nitrate and nitrite in ovarian cancer risk should be followed in other large cohort studies. (nih.gov)
  • however, the reasons for CCC being more frequent in endometriosis-related ovarian cancer and its unique characteristics are not clear. (encyclopedia.pub)
  • Because mitochondria have been fundamental in evolution to produce energy, cancer cells utilize mitochondria for survival. (encyclopedia.pub)
  • The indication was suspected ovarian cancer from solid parts found during ultrasound and CA125 level 169. (ui.ac.id)
  • Abundantly expressed in ovarian cancer clear-cell adenocarcinoma. (bioparadigms.org)
  • We detect mutational signatures in cancer cell line exomes (where matched healthy tissues are not available) by adjusting for the confounding germline mutation spectra across ancestries. (nature.com)
  • Therefore, the altered capacity of cancer cells to repair and/or replicate DNA is the basis of many classical therapies, such as platinum-based agents, and also recently introduced or upcoming therapies, such as PARP inhibitors or ATR inhibitors (reviewed in refs. (nature.com)
  • It is paramount to identify predictive markers that are associated with failures of DNA maintenance in cancer cells. (nature.com)
  • Because mutational signatures describe the state of the DNA repair machinery of a cancer cell, they may be able to serve as a drug sensitivity marker. (nature.com)
  • Ovarian cancer is the most lethal gynecologic malignancy. (biomedcentral.com)
  • Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. (biomedcentral.com)
  • One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. (biomedcentral.com)
  • A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway. (biomedcentral.com)
  • The origin and pathogenesis of epithelial ovarian cancer (EOC) have long been investigated but still poorly understood. (biomedcentral.com)
  • Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features [ 1 ]. (biomedcentral.com)
  • Over the past three decades, surgical tumor debulking, followed by platinum-based chemotherapy is the standard treatment for advanced ovarian cancer. (biomedcentral.com)
  • In terms of origin of ovarian cancer, many of researchers and gynecologic oncologists have traditionally understood that the various different ovarian tumors are all derived from the ovarian surface epithelium (mesothelium) and that subsequent metaplastic changes lead to the development of the different cell types (Table 2 ). (biomedcentral.com)
  • The age-specific incidence of ovarian epithelial cancer rises from the age of 20 to 80 and subsequently declines[ 2 ]. (biomedcentral.com)
  • B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer. (nih.gov)
  • Transmembrane or otherwise tumor-associated polypeptides specifically expressed on the surface of cancer cells as compared to normal, non-cancerous cell(s) have been identified as cellular targets for cancer diagnosis and therapy with antibodies. (justia.com)
  • Identification of such tumor-associated cell surface antigen polypeptides, i.e. tumor associated antigens (TAA), allows specific targeting of cancer cells for destruction via antibody-based therapies. (justia.com)
  • The use of antibody-drug conjugates (ADC), i.e. immunoconjugates, for the local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumor cells in the treatment of cancer (Lambert, J. (2005) Curr. (justia.com)
  • This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. (ucsf.edu)
  • Immunotherapy with monoclonal antibodies , such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (ucsf.edu)
  • It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer. (ucsf.edu)
  • A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. (ucsf.edu)
  • To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer , peritoneal primary or fallopian tube cancer. (ucsf.edu)
  • To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer. (ucsf.edu)
  • To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) in patients with recurrent platinum-sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer, as measured by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) trial outcome index and Rand Short Form (SF)-36 physical functioning scale. (ucsf.edu)
  • Community Connection: Ovarian Cancer Canada is looking for volunteers! (ovariancanada.org)
  • It said stage 2 ovarian cancer, adenocarcinoma, 10% of the cells well clear cell. (ovariancanada.org)
  • Introduction: Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. (bvsalud.org)
  • This review was conducted to summarize, in a concise and systematic manner, the available scientific data relating endometriosis to ovarian cancer, published in the past five years. (endometriosi.it)
  • Endometriosis is associated with an increased risk of developing epithelial ovarian cancer (EOC), mainly of endometrioid and clear cell subtypes. (endometriosi.it)
  • Imaging biomarkers in ovarian cancer: the role of 18F-FDG PET/CT. (espacio-seram.com)
  • Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy. (espacio-seram.com)
  • Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. (espacio-seram.com)
  • 18)F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. (espacio-seram.com)
  • Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. (espacio-seram.com)
  • Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level. (espacio-seram.com)
  • Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. (espacio-seram.com)
  • Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. (espacio-seram.com)
  • Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT. (espacio-seram.com)
  • Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. (espacio-seram.com)
  • The performance of contrast-enhanced FDG PET/CT for the differential diagnosis of unexpected ovarian mass lesions in patients with nongynecologic cancer. (espacio-seram.com)
  • 3 ] found that a pyroptosis-related signature can effectively predict the prognosis of patients with ovarian cancer. (nature.com)
  • Prior small studies have shown increased expression of sperm protein 17 (Sp17) in epithelial ovarian cancer (EOC) tissue and suggest Sp17 as a potential biomarker for EOC. (biomedcentral.com)
  • Epithelial ovarian cancer (EOC) is the fifth most common cause of female cancer-related deaths. (biomedcentral.com)
  • One CTA that has been proposed as a potential biomarker for ovarian cancer is sperm protein 17 (Sp17). (biomedcentral.com)
  • The Stem Cells & Wnt inhibitor objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer. (mi-rna.com)
  • During 2001-2005, clinical records of 118 patients with epithelial ovarian cancer were collected in Tokushima prefecture. (mi-rna.com)
  • Human pancreatic cancer cell line. (maayanlab.cloud)
  • A immortal human stomach-derived cell line cell that has the characteristics: Stomach cancer, but producing Nagao-type alkaline phosphatase. (maayanlab.cloud)
  • Phase II/III Study of Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. (kaiser.org)
  • This randomized phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. (kaiser.org)
  • It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer. (kaiser.org)
  • The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer. (onclive.com)
  • The addition of the DNA-based interleukin-12 (IL-12) immunotherapy GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer, according to data from the phase 1 OVATION 1 trial (NCT02480374). (onclive.com)
  • As patients with advanced ovarian cancer have a poor prognosis, these data are particularly encouraging. (onclive.com)
  • For patients with epithelial ovarian cancer, there remains an unmet need for treatments that not only improve survival outcomes, but also reduce the rate of disease recurrence. (onclive.com)
  • IL-12 has been associated with adaptive immune responses against cancer cells, and responses to the pluripotent cytokine have been demonstrated across cancer types. (onclive.com)
  • Moreover, treatment with GEN-1 has been shown to elicit durable local levels on IL-12, and in preclinical models, demonstrate promising safety and efficacy in patients with ovarian cancer. (onclive.com)
  • Binding of these available anti-AXL antibodies are also not consistent across cancer cell lines. (justia.com)
  • and mechanisms of eicosapentaenoic acid (EPA) in ovarian cancer cell growth are poorly understood. (biotech-angels.com)
  • Ten (62.5%) of the ovarian cancer cases were diagnosed by ultrasonography during a prenatal checkup or at the time of initial pregnancy diagnosis. (biomedcentral.com)
  • Ovarian cancer is the leading gynecologic cancer diagnosed in North America and because related symptoms are not disease specific, this often leads to late detection, an advanced disease state, and the need for chemotherapy. (biomedcentral.com)
  • Ovarian cancer is frequently sensitive to chemotherapy at diagnosis but rapid development of drug resistance leads to disease progression and ultimately death in the majority of patients. (biomedcentral.com)
  • We have generated model systems to explore drug resistance in ovarian cancer, which have revealed a key pathway related to the spindle assembly checkpoint underlying paclitaxel resistance in ovarian cell lines. (biomedcentral.com)
  • Ovarian cancer is the most common gynecological cancer diagnosed in North America and has one of the lowest survival rates among all cancers [ 2 ]. (biomedcentral.com)
  • Paclitaxel is a frontline therapy used to treat advanced ovarian cancer, and in many instances, paclitaxel is combined with platinum based therapeutic drugs, such as carboplatin to improve overall survival [ 4 , 7 ]. (biomedcentral.com)
  • We report isolation of Francisella novicida -causing bacteremia in a woman from Thailand who was receiving chemotherapy for ovarian cancer. (cdc.gov)
  • Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. (cdc.gov)
  • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer. (cdc.gov)
  • Fifty-one percent of women had endometrial or ovarian cancer diagnosed first as the sentinel cancer. (medscape.com)
  • ctDNA is currently the most common form of liquid biopsy, a term used to refer to utilizing circulating cancer cells, DNA and other omic markers from blood or fluid sample. (cdc.gov)
  • Current National Comprehensive Cancer Network (NCCN) 2022 guidelines specific to NSCLC (V5.2022) advise plasma cell-free/circulating tumor DNA testing should not be used in lieu of histologic tissue diagnosis, although it can be considered in specific clinical circumstances (i.e., if a patient is not suitable for invasive tissue sampling, if insufficient material following pathologic confirmation or incomplete assessment of all recommended biomarkers in the initial diagnostic setting). (cdc.gov)
  • An FDA companion diagnostic device received premarket approval, which includes indications for NSCLC and prostate cancer, and was updated to also include ovarian and breast cancer genetic testing using cfDNA. (cdc.gov)
  • Between February 2009 and July 2013, 402 patients with clinical stage I non-small cell lung cancer (NSCLC) underwent "non-grasping en bloc MLND" conducted by one surgical team. (medscape.com)
  • Angiosarcoma of the ovary is rare but represents an aggressive type of malignant ovarian neoplasms. (hindawi.com)
  • Objective: Discuss the complications of laparoscopic ovarian cystic neoplasms. (ui.ac.id)
  • Ovarian tumors account for a considerable proportion of clinically relevant neoplasms in females, exhibiting a wide range of age at presentation (from infant to elderly patients). (biomedcentral.com)
  • Epithelial neoplasms of the ovary are thought to arise either directly or indirectly from the ovarian surface epithelium according to incessant ovulation theory[ 4 ]. (biomedcentral.com)
  • Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation. (nih.gov)
  • However, how Sp17 expression varies with histology, grade, and stage of EOC and its expression in other ovarian neoplasms has not been defined. (biomedcentral.com)
  • The study included 982 patients with benign, borderline, and malignant ovarian neoplasms and normal ovary. (biomedcentral.com)
  • Sp17 is highly expressed in benign, borderline, and low grade malignant serous ovarian neoplasms and can be quantified in serum. (biomedcentral.com)
  • At present, serum CA-125 is the most extensively used biomarker to preoperatively discriminate between benign and malignant ovarian neoplasms, detect recurrence, and monitor response to treatment. (biomedcentral.com)
  • SFTs of the pleura are localized mesenchymal neoplasms composed of fibroblastlike cells believed to arise from the subpleural connective tissue. (medscape.com)
  • These findings suggest that these two different types of ovarian cancers develop along different molecular pathways. (biomedcentral.com)
  • We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). (biomedcentral.com)
  • They represent 30% of all epithelial tumors and 80%-85% of all ovarian cancers. (biomedcentral.com)
  • Endometrioid adenocarcinomas account for about 75 to 80% of endometrial cancers. (msdmanuals.com)
  • simply because critical players in the maintenance of self-renewal and pluripotency in normal and cancers stem cells. (biotech-angels.com)
  • From this study, we reaffirm the clear and significant benefits of prenatal checkups starting at an early gestational age for the detection of gynecological cancers during pregnancy. (biomedcentral.com)
  • However, because the data source highly depends upon the entire occurrence of tumor types, the provisional and final analyses of ovarian cancers have primarily focused on serous ovarian adenocarcinomas, rather than on EAOC including clear cell and endometrioid ovarian carcinomas. (bibf1120.com)
  • EAOC, especially ovarian clear cell carcinomas, is well recognized to have greater resistance to platinum-based chemotherapy, a more aggressive clinical course, and more malignant behavior than other types of ovarian cancers [19C21]. (bibf1120.com)
  • [ 1 ] Approximately 80-90% of vaginal cancers are squamous cell carcinomas, while 5-10% are adenocarcinomas. (medscape.com)
  • L'objectif de cette étude était de déterminer la fréquence des cancers gynécologiques en pratique oncologique à Lomé et d'en étudier les aspects épidémiologiques et histo-cliniques. (bvsalud.org)
  • Il s'agitd'une étude rétrospective et descriptive portant sur tous les cancers gynécologiques reçus en oncologie entre le 1erJanvier 2016 et le 31 Décembre 2021. (bvsalud.org)
  • It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. (biomedcentral.com)
  • Type I tumors include low-grade serous, low-grade endometrioid, clear cell and mucinous carcinomas and type II include high-grade serous, high-grade endometrioid and undifferentiated carcinomas. (biomedcentral.com)
  • Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future. (biomedcentral.com)
  • However, the vast majority of malignant ovarian tumors (80%-85%) are classified as epithelial tumors (carcinomas). (biomedcentral.com)
  • In contrast, 80%-90% of ovarian carcinomas are detected after the age of 40, and 40% of these tumors are detected after the age of 65. (biomedcentral.com)
  • Carcinomas are characterized by cell proliferation, nuclear atypia, and stromal invasion. (biomedcentral.com)
  • Ovarian carcinomas are characterized by a Müllerian morphology although the ovaries do not originate from the Müllerian ducts. (biomedcentral.com)
  • Indeed, it has been postulated that the possible mechanisms by which repetitive ovulation could influence the development of ovarian carcinomas include an increased formation of inclusion cysts, repeated bathing of the surface epithelium by an estrogen-rich follicular fluid, excessive production of growth factors or cytokines, and an aberration of the repetitive repair process that follows the trauma to the surface epithelium as a consequence of ovulation. (biomedcentral.com)
  • Serous carcinomas are thought to be derived from the fallopian tubes through foci of endosalpingiosis, which are inclusion cysts from the tubal epithelium at the ovarian and peritoneal surface. (biomedcentral.com)
  • Type II tumors are usually high-grade and include grade 3 endometrioid carcinomas and tumors with nonendometrioid histology (eg, serous, clear cell, mixed cell, undifferentiated, carcinosarcoma). (msdmanuals.com)
  • In renal very clear cell carcinomas Specifically, which display pathological commonalities with very clear cell ovarian carcinomas, high SOD2 manifestation demonstrates better mitochondrial ROS and function level of resistance, and improved SOD2 manifestation correlates with poor prognosis [14]. (bibf1120.com)
  • Ovarian clear cell carcinomas have poor prognosis because of resistance to current chemotherapy protocols, based on platinum and taxane [19]. (bibf1120.com)
  • This study confirmed the following findings: a novel therapeutic strategy for clear cell ovarian carcinomas and/or other EAOCs, in which SOD2 is strongly expressed, should be established. (bibf1120.com)
  • Approximately eighty percent of endometrial carcinomas are endometrioid adenocarcinomas. (medscape.com)
  • Other histologic subtypes include adenosquamous, clear cell, and papillary serous carcinomas. (medscape.com)
  • Enzyme-linked immunosorbent assay (ELISA) was for IL-6 levels in peritoneal fluid and cell culture supernatant. (endometriosi.it)
  • Increased levels of IL-12 and interferon-g were seen in the peritoneal washings because of the treatment, as well as increased levels of myeloid dendritic cells and T effector memory cells in the peritoneal fluid. (onclive.com)
  • Stage I and II disease with squamous cell lesions at the apex or the upper posterior or lateral portions of the vagina may be treated surgically. (medscape.com)
  • Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. (biomedcentral.com)
  • Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (ucsf.edu)
  • They all had endometriosis for a long time and had undergone ovarian cyst removal due to a chocolate cyst. (bvsalud.org)
  • Human cell line derived from ovarian serous cyst adenocarcinoma. (riken.jp)
  • On December 10th, 1990, the patient was diagnosed as appendicitis and ovarian cyst, and had appendecetomy and left ovarian chocolate cystectomy at a local hospital. (scirp.org)
  • Invasive mucinous adenocarcinoma is uncommon and usually arises in the background of benign or borderline tumors. (hindawi.com)
  • Approximately 75%-80% of ovarian tumors are benign, occurring in patients under 40 years of age. (biomedcentral.com)
  • Benign epithelial tumors (adenoma and cystadenoma) are characterized by the absence of cell proliferation and invasion. (biomedcentral.com)
  • Benign clear cell adenofibroma of the ovary. (nih.gov)
  • Despite being initially considered a benign disease, it is widely thought nowadays that endometriosis and especially ovarian endometriomas are neoplastic conditions with the potential to become malignant. (endometriosi.it)
  • The usefulness of 18F-FDG-PET/CT in discriminating benign from malignant ovarian teratomas. (espacio-seram.com)
  • Angiosarcoma may present a challenge in intraoperative frozen section diagnosis of an ovarian mass. (hindawi.com)
  • The frozen section diagnosis was at least mucinous borderline tumor, pending adequate tissue sampling for permanent sections to rule out mucinous adenocarcinoma. (hindawi.com)
  • At diagnosis, 1-2% are bilateral and 90-95% of cases are germ cell tumours (GCT) [ 6 ]. (uroweb.org)
  • The invention also relates to methods of using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. (justia.com)
  • You may find others here that have clear cell diagnosis. (ovariancanada.org)
  • Procedures used in the diagnosis and evaluation of a germ cell ovarian tumour include pelvic examination, ultrasound, CT scan and biopsy. (cancertame.com)
  • Five months before seeking treatment, she received a diagnosis of advanced stage clear cell adenocarcinoma of the ovary with metastasis to peritoneum, spleen, uterus, and multiple abdominal lymph nodes. (cdc.gov)
  • The recommendations based on a systematic review determined that there was insufficient evidence to inform the use of cfDNA or ctDNA for diagnosis of primary lung adenocarcinoma or identification of mutations at the time of EGFR TKI resistance. (cdc.gov)
  • Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy. (espacio-seram.com)
  • Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy. (espacio-seram.com)
  • Endometrial adenocarcinoma is the most common gynecologic malignancy in the United States. (medscape.com)
  • found that pyroptosis-related genes can be used for prognostic prediction of skin cutaneous melanoma and lung adenocarcinoma, respectively. (nature.com)
  • A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma. (cdc.gov)
  • Seromucinous tumor cells were positive for estrogen receptor (ER) and progesterone receptor (PgR) but negative for Napsin A, p504S, and HNF1B. (hindawi.com)
  • These tumor cells had clear cytoplasm and a hobnail-shaped appearance (Figure 2(c) ). (hindawi.com)
  • Pneumoperitoneum might cause seeding of tumor cells. (ui.ac.id)
  • No. 4,975,278) allows targeted delivery of the drug moiety to tumors, and intracellular accumulation therein, where systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells as well as the tumor cells sought to be eliminated (Baldwin et al (1986) Lancet pp. (justia.com)
  • Initial, the high SOD2 manifestation of tumor cells is an unhealthy prognostic element for EAOC. (bibf1120.com)
  • In this paper, we consider three such features: tumor mutation burden (TMB, i.e., the total number of SPMs), SCNA burden, and the degree of (genetic) intra-tumor heterogeneity (ITH), which refers to the fact that tumor cells can be grouped in subclones such that the cells within one subclone share similar sets of somatic mutations. (biomedcentral.com)
  • Circulating tumor DNA (ctDNA) is a specific type of cfDNA that originates from a primary tumor, circulating tumor cells or metastasized cells. (cdc.gov)
  • We have generated isogenic paclitaxel resistant cell lines from their corresponding native cell lines which reflect the 3 most common ovarian histologic subtypes, these include serous, clear cell and endometrioid subtypes [ 2 ]. (biomedcentral.com)
  • The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated. (bmj.com)
  • Understanding the fundamental biology of ovarian CCC might help in the development of novel therapeutic strategies. (encyclopedia.pub)
  • Suitability of an antigen for therapy is dependent on various factors including but not limited to the nature of the antigen (e.g. accessibility, abundance, location of expression on cancerous cells etc.), therapeutic approach, antibody affinity and other pharmacokinetic properties. (justia.com)
  • Lastly, through gene expression profiling we have demonstrated disruption of the spindle assembly checkpoint in the paclitaxel resistant cell lines, indicating a potential therapeutic pathway. (biomedcentral.com)
  • We isolated and characterized cell cultures from eutopic endometrium and endometriotic lesions of women with malformations of the internal reproductive organs. (endometriosi.it)
  • at the same time, they demonstrated in vitro immunophenotypic differences from cell cultures of eutopic and ectopic endometrium of women without developmental abnormalities, which suggests their functional difference. (endometriosi.it)
  • The cells from eutopic endometrium and from ectopic endometriotic lesions can be used as the model for studying of the etiology and pathogenesis of endometriosis and for testing new drugs for this specific group of patients. (endometriosi.it)
  • Markers CD90 and CD117 were identified as promising molecules for the development of minimally invasive diagnostics of endometriosis based on cell cultures from eutopic endometrium. (endometriosi.it)
  • Ovarian epithelial tumors are subclassified into several categories based on two criteria: 1) the degree of epithelial proliferation and invasion and 2) the histotype of the epithelium composing the tumor. (biomedcentral.com)
  • It is hypothesized that the epithelium covering the ovarian surface and the peritoneum retains the potential for Müllerian differentiation given the proximity to the coelomic epithelium from which the Müllerian ducts are derived. (biomedcentral.com)
  • These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. (biomedcentral.com)
  • According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord stromal tumors (8%)[ 1 ]. (biomedcentral.com)
  • Malignant germ cell and sex-cord stromal tumors comprise approximately 10% of all malignant ovarian tumors. (biomedcentral.com)
  • Borderline tumors are characterized by cell proliferation and a minor degree of nuclear atypia without stromal invasion. (biomedcentral.com)
  • The CCL17-CCR4 axis between endometrial stromal cells and macrophages contributes to the high levels of IL-6 in ectopic milieu. (endometriosi.it)
  • The aim of this study was to investigate whether the cross talk between endometrial stromal cells (ESCs) and macrophages contributes to the elevated IL-6 production. (endometriosi.it)
  • The remaining 15 per cent of the ovarian tumours are germ cell tumours, stromal tumours and the borderline tumours. (cancertame.com)
  • Ovarian germ cell tumours and stromal tumours constitute about 10 per cent of the ovarian tumours. (cancertame.com)
  • The stromal tumours include granulosa cell tumour and Sertoli-Leydig tumour. (cancertame.com)
  • Ovarian germ cell tumours and stromal tumours affect young women usually below 20 years of age. (cancertame.com)
  • Ovarian germ cell tumours and stromal tumours remain asymptomatic during initial stages of the disease. (cancertame.com)
  • Common presenting symptoms of the ovarian germ cell tumours and stromal tumours include mass in the abdomen and vaginal bleeding. (cancertame.com)
  • We have generated paclitaxel resistant ovarian cell lines from their corresponding native cell lines to determine driver mechanisms of drug resistance using gene expression arrays. (biomedcentral.com)
  • These paclitaxel resistant ovarian cells demonstrate: (1) Increased IC 50 for paclitaxel and docetaxel (10 to 75-fold) and cross-resistance to anthracyclines (2) Reduced cell apoptosis in the presence of paclitaxel (3) Gene depletion involving mitotic regulators BUB1 mitotic checkpoint serine/threonine kinase, cyclin BI (CCNB1), centromere protein E (CENPE), and centromere protein F (CENPF), and (4) Functional data validating gene depletion among mitotic regulators. (biomedcentral.com)
  • Cells were exposed to an incremental dose escalation of paclitaxel (2 nM) for approximately 2 passages, up to a final concentration of 25 nM, once paclitaxel resistance was achieved. (biomedcentral.com)
  • established from the solid omental metastasis of a mucinous papillary adenocarcinoma of the ovary of a 36-year-old woman in 1979. (maayanlab.cloud)
  • An abdominal computed tomography scan revealed bilateral ovarian tumors and uterine leiomyoma. (hindawi.com)
  • A 35 cm right ovarian mass submitted for intraoperative consultation was a multicystic mucinous tumor with an 8 cm area of hemorrhagic lesion between cystic locules. (hindawi.com)
  • Ultrasonography and abdominal computed tomographic scan revealed a 26 cm right ovarian solid-cystic mass with internal septation. (hindawi.com)
  • A 35 cm right ovarian mass was identified, with focal previous rupture of the external surface. (hindawi.com)
  • The right ovarian mass was submitted for intraoperative consultation. (hindawi.com)
  • Ovarian seromucinous borderline tumors (SMBTs) are rare. (hindawi.com)
  • The peak incidence is in the third decade of life for non-seminomatous germ cell tumour (NSGCT) and mixed GCT patients, and in the fourth decade for seminoma testis (ST) patients. (uroweb.org)
  • Serum concentrations were higher in patients with Sp17 tissue expression, and the highest concentrations were noted among patients with serous and clear cell adenocarcinomas. (biomedcentral.com)
  • Method: Case report A-52 year old female with 2 parities, complained of a lump at anterior abdominal wall during chemothe rapy for clear cell ovarian adenocarcinoma after total hysterectomy and bilateral salphingooophorec tomy by lapa roscopy. (ui.ac.id)
  • For stage I vaginal adenocarcinoma, total radical vaginectomy and hysterectomy with lymph node dissection are indicated. (medscape.com)
  • The tumor genome atlas (TCGA) data source cannot claim that SOD2 is really a prognostic sign in ovarian tumor. (bibf1120.com)
  • Mucinous tumor is a common type of ovarian epithelial tumors. (hindawi.com)
  • Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. (cdc.gov)
  • Altogether there are four main datasets, namely 409 "SLCs" in 59 tissue types and 56 cell lines, and 48 ABCs in the same tissue types and cell lines. (biorxiv.org)
  • Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. (elsevierpure.com)
  • Two cell lines derived from ovarian clear cell adenocarcinoma (RMG-I and RMG-V), with different levels of invasive potential in an invasion assay, were used. (elsevierpure.com)
  • Dive into the research topics of 'Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. (elsevierpure.com)
  • Most malignant post-pubertal GCTs originate from germ cell neoplasia " in situ " (GCNIS). (uroweb.org)
  • Germ cell ovarian tumour arises from the germ cells (the cells that give rise to ovaries during the foetal development). (cancertame.com)
  • In stage I, a germ cell ovarian tumour is localised to one or both ovaries. (cancertame.com)
  • I n stage III, a germ cell ovarian tumour metastasises to the abdominal lymph nodes and abdominal organs such as the intestines and surface of the liver. (cancertame.com)